Is US Preparing For A Quademic 2025?

Updated Jan 15, 2025 | 03:10 PM IST

SummaryQuademic 2025: It is all caused by seasonal infections, including common flu, Covid-19, and respiratory syncytial virus (RSV) that dominate the winter season in the US. This year, norovirus also joined the list, which has further increased the load on the healthcare.
Is US preparing for a quademic?

Credits: Canva

Quademic 2025: Hospitals in the United States are dealing with a surge in patients admission, the reason is the quademic it is dealing with at this moment. This has led to an influx of patients. It is all caused by seasonal infections, including common flu, Covid-19, and respiratory syncytial virus (RSV) that dominate the winter season in the US. This year, norovirus also joined the list, which has further increased the load on the healthcare.

The healthcare company founded in academics M Health Fairview, confirmed that their hospitals are overflowing due to the quademic.

Is US able to cope with Quademic 2025?

The hospitals of M Health Fairview's volume is up by 30% and as a results, patients are being treated in the hallways and in alternative care areas. There is also a longer wait time and shortages for resources that are required to treat these emergencies. This has also impacted other life-threatening emergencies like heart attacks and strokes, as the healthcare resources and caregivers are occupied with the surge in seasonal cases.

ALSO READ: Birmingham Struggles With 4 Different Virus Hits, Know What They Are

What are these quademic infections?

Common cold and flu: The common cold and influenza (flu) are perhaps the most well-known illnesses that peak during the fall. As temperatures drop and humidity levels fluctuate, viruses that cause colds and the flu become more active. The flu, in particular, can be more severe than a common cold, leading to complications such as pneumonia, especially in vulnerable populations like the elderly and those with pre-existing health conditions. Symptoms include a runny nose, sore throat, coughing, fever, and body aches.

Covid-19: As per the World Health Organization, Coronavirus disease or COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Most people infected with this virus will experience mild to moderate respiratory illness and recover without requiring special treatment, However, there could be some cases of seriously ill patients who may require medical attention. It is also because of the other existing medical conditions like cardiovascular diseases, diabetes, chronic respiratory diseases, cancers, or older age.

The best way to protect against this virus is by following social isolation form those who are infected, using mask to prevent droplets from infecting others when you cough or sneeze and to wash your hands for 20 seconds frequently.

RSV or Respiratory Syncytial Virus: As per the Centers of Diseases Control and Prevention (CDC), RSV is a common respiratory virus that infects nose, throat and lungs. Though symptoms are similar to the viruses like flu or COVID-19, the disease in itself is different. It also peaks during the winter season, especially between December and January.

However, the main difference between RSV and other respiratory illness, above mentioned is that RSV can cause pneumonia or bronchiolitis, especially for those who are over the age of 50 or with an existing heart or lung disease.

Norovirus: It is a number 1 cause of foodborne illness in the US and this happens when virus gets into the food and then it accidentally enters your mouth. These particles are from faeces or vomit from infected people, or can be transmitted via contaminated food and water. It could also spread by touching unclean surfaces like door handles or cutlery.

For most people, having norovirus is unpleasant, but mild and recovery could be made in 1 to 2 days. However, it could be more serious for babies, older people and anyone with any existing health condition.

End of Article

India Administers 1 Crore HPV Vaccine Doses In 9 Months, Covering 87% Of Eligible Girls

Updated Nov 22, 2026 | 11:00 AM IST

SummaryThe Ministry of Health and Family Welfare recently announced that India has administered HPV vaccine in nearly 87% of eligible teenage girls, which equals roughly 1.2 crore girls.
India Administers 1 Crore HPV Vaccine Doses In 9 Months, Covering 87% Of Eligible Girls

Credit: AI image

India has administered more than 1 crore doses of the human papillomavirus (HPV) vaccine in less than nine months since it launched its nationwide vaccination campaign.

This means the country has covered nearly 87% of its annual target cohort of 14-year-old girls. The milestone marks a major step towards preventing cervical cancer, which is largely caused by repeated HPV infections.

India Hits Its HPV Vaccination Target

Also read: World Cervical Cancer Elimination Day 2026: WHO Calls For HPV Vaccination, Screening & Early Treatment

According to the Ministry of Health and Family Welfare, the campaign has reached nearly 87% of its estimated annual target of 1.2 crore girls, based on 2021 population estimates from the Registrar General of India.

The vaccination drive was started in February 2026 and provides free, voluntary single-dose HPV vaccination to eligible 14-year-old girls at designated government health facilities.

Six states, Gujarat, Uttar Pradesh, Andhra Pradesh, Mizoram, Madhya Pradesh and Bihar, have reported 100% coverage of their target populations.

Among other states, Assam has recorded 95.63% coverage, followed by Telangana at 95.28%, Karnataka at 93.16% and Uttarakhand at 90.17%. Chhattisgarh and Rajasthan have crossed 80% coverage, while Kerala, Tamil Nadu and Odisha have achieved more than 70%.

In terms of the number of girls vaccinated, Uttar Pradesh leads with more than 29.33 lakh, followed by Bihar with 13.70 lakh and Gujarat with 7.75 lakh.

How Does HPV Vaccine Prevent Cervical Cancer?

Also read: Menstrual Blood-Based Self-Sampling Cervical Cancer Test Gets Patent-Know Everything About It

Almost all cervical cancer cases are caused by repeated infection with high-risk types of human papillomavirus, a common virus transmitted through sexual contact.

Most HPV infections clear naturally without causing health problems. The progression from HPV infection to cervical cancer generally takes 15–20 years, but it can happen faster in women with weakened immune systems.

HPV vaccination helps prevent infections caused by HPV types that cause cancer before exposure to the virus. Vaccinating girls at age 14 aims to provide protection before they are likely to encounter HPV. The vaccine is a preventive intervention. It does not treat an existing HPV infection or cervical cancer.

India Is Expanding HPV Vaccination Coverage

Also read: About 7.9% Of Women In Kerala Are Affected By Cervical Cancer; Why Early Detection Is Important

The government says the campaign's progress has been supported by coordination between the Centre, state governments, district administrations, healthcare professionals and frontline workers, including ASHAs and ANMs.

The U-WIN digital platform is being used for beneficiary tracking, monitoring vaccination coverage, maintaining digital records and identifying eligible girls yet to receive the vaccine. Parents can also use the platform to book vaccination slots and obtain digital certificates.

Vaccination sessions are conducted at designated government health facilities under the supervision of trained medical officers. Arrangements have also been made for identifying and managing adverse events after vaccination.

Cervical Cancer Prevention

Cervical cancer remains a major public health concern in India, despite being largely preventable through HPV vaccination.

The World Health Organization's cervical cancer elimination strategy aims for 90% of girls to be fully vaccinated against HPV by age 15, 70% of women to undergo screening by ages 35 and 45, and 90% of women diagnosed with cervical disease to receive appropriate treatment.

Cervical cancer prevention entails HPV vaccination, regular screening and timely treatment of precancerous changes.

End of Article

Pancreatic Cancer Breakthrough? New Drug Combo Controls Tumour Growth In 90% Of Patients

Updated Nov 22, 2026 | 09:37 AM IST

SummaryThe combination includes daraxonrasib, an experimental targeted cancer drug, and two chemotherapy medicines, gemcitabine and nab-paclitaxel, designed to treat one of the most deadliest cancers.
Pancreatic Cancer Breakthrough? New Drug Combo Controls Tumour Growth In 90% Of Patients

Credit: AI image

In what can be described as a major breakthrough, a new treatment combination has shown tremendous promise in advanced pancreatic cancer treatment. A recent early-stage clinical trial showed that the combo shrank tumours in more than 60% of patients and controlled disease progression in 90% of patients.

The findings raise hope for pancreatic cancer, which is often diagnosed late as well as has limited treatment options. Despite positive outcomes, larger trials are needed to establish how much the treatment improves survival.

More About The Pancreatic Cancer Treatment Trial

Also read: Experimental Vaccine For Blood Cancer Cuts Death Risk By 41% In Trial: How Does It Work?

The combination includes daraxonrasib, an experimental targeted cancer drug, alongside two chemotherapy medicines, gemcitabine and nab-paclitaxel.

The updated results from the Phase 1/2 RMC-GI-102 trial were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.

The study involved 61 patients with metastatic pancreatic adenocarcinoma who had not previously received treatment for their metastatic disease. Participants received the combination and were followed for a median of 18.3 months.

A 90.2% control in disease was reported, meaning the cancer either shrank or remained stable. The objective response rate, which measures tumours that shrank significantly or disappeared, was 60.7%. This included complete responses in 8.2% of patients, whose tumours were no longer detected.

Median progression-free survival was 12.8 months, meaning patients lived a median of nearly 13 months without their cancer progressing or dying. The estimated proportion of patients alive at one year was 76.6%.

Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, who presented the findings, said “this is the closest to cure”. He also said that he had never seen so many tumours disappear in patients whose cancer had spread.

He also said, “We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival."

He added, “The median follow-up is 18 months. Just imagine, in an average of 18 months your disease just disappears on the CT scan … that’s closest to complete remission … it’s incredible.”

How Does The New Drug Combination Work?

Also read: Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer

Daraxonrasib, also known as RASONQUE, targets RAS, which drives cell growth. Mutations in RAS, especially KRAS, can keep these growth signals on, allowing pancreatic cancer cells to multiply uncontrollably.

The drug is designed to inhibit active RAS proteins and disrupt the signals that cancer cells depend on for growth and survival. Researchers are combining it with chemotherapy to attack the cancer through different mechanisms.

Gemcitabine interferes with cancer cell DNA synthesis, while nab-paclitaxel disrupts microtubules, structures essential for cell division. Combining these drugs with targeted RAS inhibition could produce more sustained responses.

A Major Breakthrough

Also read: Health Canada Warns Against Faulty Radon Detectors: How The Invisible Gas In Your Home May Cause Lung Cancer

Pancreatic cancer remains one of the most difficult cancers to treat once it has spread beyond the pancreas. Many patients are diagnosed at an advanced stage, when surgery may no longer be possible.

The RAS signalling mechanism has long been considered a challenging target for cancer treatment. The development of drugs capable of fighting this has therefore opened a new avenue of research, especially pancreatic cancers driven by RAS mutations.

The trial's response rates and duration of disease control are encouraging. However, it was a small, open-label study without a chemotherapy comparison group.

Researchers cannot determine yet how much of the benefit came from daraxonrasib rather than chemotherapy or whether the combination will significantly extend survival.

Daraxonrasib is being investigated in larger clinical trials to determine its effectiveness and safety. A Phase 3 trial, RASolute 303, is comparing daraxonrasib alone, daraxonrasib combined with gemcitabine and nab-paclitaxel, and chemotherapy alone in patients with previously untreated metastatic pancreatic cancer.

These results will help establish whether the promising early findings translate into a meaningful improvement in survival and whether the combination could become a new treatment option.

End of Article

PJ.2.1 Is Now Variant Under Monitoring After Detection In 18 Countries: Should You Worry About Its 24 Mutations?

Updated Nov 20, 2026 | 11:00 PM IST

SummaryThe WHO has designated COVID-19 variant PJ.2.1, which has 24 spike protein changes, as a Variant Under Monitoring after sequences were reported from 18 countries. It currently assesses its additional global public health risk as low, but says more data are needed to determine whether it causes more severe illness.
PJ.2.1 Is Now Variant Under Monitoring After Detection In 18 Countries: Should You Worry About Its 24 Mutations?

Credit: iStock

The World Health Organization (WHO) has designated COVID-19 variant PJ.2.1, a descendant of the JN.1 lineage with 24 spike protein changes, as a Variant Under Monitoring (VUM). As of November 8, the variant had been detected in 18 countries, with its share of reported sequences increasing particularly in Canada and the United States.

"Considering the available evidence, the additional public health risk posed by PJ.2.1 is evaluated as low at the global level, with low confidence," the WHO said in its initial risk evaluation published by its Technical Advisory Group on Virus Evolution (TAG-VE).

Laboratory findings suggest that the variant does not show substantial additional antibody escape compared with other circulating variants. Blood samples from recipients of LP.8.1- and XFG-adapted vaccines were also able to neutralize it in laboratory tests.

However, there is insufficient clinical data to determine whether PJ.2.1 causes more severe illness.

What Is COVID Variant PJ.2.1? How Widely Has It Spread?

Also read: New COVID Variant PJ.2.1 Spreading Globally: Is India At Risk, Are There New Symptoms?

According to the WHO report, "PJ.2.1 is a highly mutated variant with 24 amino acid differences in the Spike protein alone."

First identified in Canada, laboratory studies indicate that it binds more strongly to human ACE2 receptors, which the virus uses to enter cells. However, stronger receptor binding does not necessarily mean faster transmission between people.

The WHO noted that increased receptor binding "may contribute to the observed growth, but do not directly establish increased transmissibility in humans."

The proportion of PJ.2.1 among available global sequences increased from 1% in epidemiological week 33 to 11.6% in week 41, according to the WHO.

As of November 8, 2026, 722 sequences had been submitted to the GISAID, an open access database, from 18 countries.

Can Existing Vaccines Protect Against PJ.2.1?

Read More: New COVID-19 Variant PJ.2.1 Spreads Globally: WHO Says Symptoms Resemble Cold, Flu

In a study involving plasma from 36 recipients of an LP.8.1-adapted vaccine, researchers found no greater antibody evasion against PJ.2.1 than against most tested variants.

Another study involving 22 participants found that neutralisation titres against PJ.2.1 increased 2.8-fold, from 228 before vaccination to 642, at a median of 14 days after an XFG-adapted mRNA vaccine.

These findings suggest that vaccine-induced antibodies can neutralize PJ.2.1 in laboratory tests. However, they do not establish real-world vaccine effectiveness against infection or severe disease, the WHO report said.

Does PJ.2.1 Cause More Severe Disease?

"There is currently no evidence establishing greater disease severity associated with PJ.2.1, although comparative clinical data remain limited," the WHO said.

The agency has called for further studies to assess vaccine effectiveness, compare hospitalisations and severe disease outcomes, evaluate antiviral susceptibility and strengthen genomic surveillance.

Dr Gopakumar, Senior Consultant and Head of the Department of Internal Medicine at Apollo Adlux Hospital, Kerala, said the number of mutations alone does not determine how dangerous a variant is.

"The emergence of the new COVID-19 variant PJ.2.1 highlights the virus’s continued ability to evolve. While the reported 24 mutations, particularly in the spike protein, have attracted attention, the number of mutations alone does not determine how dangerous a variant is. What matters clinically is whether these changes make the virus more transmissible, help it evade existing immunity or increase the risk of severe illness," he told HealthandMe.

Dr Navneet Sood, Associate Director and Senior Consultant, Pulmonology, Dharamshila Narayana Superspeciality Hospital, Delhi, added that current evidence does not indicate an increased impact on disease severity compared with previous variants.

"While it is safe to say that the evidence currently shows that there is no increased impact of PJ.2.1 compared to previous variants in disease severity, the WHO's variant surveillance system is still monitoring the potential for new variants to emerge and experts have emphasized the need for genomic monitoring. Public awareness should be centred on identifying respiratory symptoms, testing if required, and taking additional precautions for vulnerable people," he told HealthandMe.

Should You Be Worried?

The WHO currently assesses the additional global public health risk from PJ.2.1 as low, although confidence in this assessment remains limited.

There is no need to panic, but experts advise people to remain vigilant. Older adults, immunocompromised individuals and those with chronic illnesses should take particular care. Maintaining respiratory hygiene, ensuring adequate ventilation and seeking medical advice if respiratory symptoms develop remain sensible precautions.

End of Article